ZIOPHARM Oncology
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of ZIOPHARM Oncology generated cash of -$57,013,000, which is less than the previous year. Cash used in financing activities reached the amount of $102,119,000 last year. Net change in cash is therefore $35,328,000.
Cash Flow
| 2011 | -38.83M | -1.15M | 84.31M |
|---|---|---|---|
| 2012 | -78.83M | -1.55M | 48.98M |
| 2013 | -59.50M | -131K | 54.53M |
| 2014 | -36.65M | -193K | 11.44M |
| 2015 | -10K | -412K | 98.33M |
| 2016 | -58.32M | -551K | -788K |
| 2017 | -54.66M | -737K | 45.29M |
| 2018 | -49.45M | -459K | 40.31M |
| 2019 | -40.85M | -284K | 59.15M |
| 2020 | -57.01M | -9.77M | 102.11M |
ZIOP Cash Flow Statement (2011 – 2020)
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 79.74M | 61.72M | 71.33M | 81.05M | 140.71M | 42.80M | 68.20M | 73.30M | 104.71M | 60.39M |
Operating activities | ||||||||||
Net income | -79.97M | -117.79M | -53.11M | -54.32M | -165.29M | -120.08M | -31.78M | -57.10M | -96.13M | -63.77M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 1.12M | 629K | 575K | 369K | 290K | 357K | 462K | 738K | 658K | 268K |
Stock-based compensation expense | 6.82M | 7.34M | 7.53M | 8.45M | 8.45M | 7.99M | 4.74M | 3.50M | 4.88M | 2.75M |
| Deferred income tax benefit | 6.82M | 7.34M | 7.53M | 8.45M | 8.45M | 7.99M | 4.74M | 3.50M | 4.88M | 2.75M |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | -1.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 54K | 199K | -3.70M | 4.26M | -1.85M | 4K | 1.58M | -1.08M | -218K | 696K |
Cash generated by operating activities | -57.01M | -40.85M | -49.45M | -54.66M | -58.32M | -10K | -36.65M | -59.50M | -78.83M | -38.83M |
Investing activities | ||||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -9.77M | -284K | -459K | -737K | -551K | -412K | -193K | -132K | -1.55M | -1.15M |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -9.77M | -284K | -459K | -737K | -551K | -412K | -193K | -131K | -1.55M | -1.15M |
Financing activities | ||||||||||
Common Stock Issued | 101.67M | 6.08M | 47.10M | 47.27M | 0 | 94.32M | 0 | 53.88M | 49.17M | 71.20M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | -653K | -1.62M | -2.05M | -1.50M | -552K | -544K | -498K | -546K | -274K |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 102.11M | 59.15M | 40.31M | 45.29M | -788K | 98.33M | 11.44M | 54.53M | 48.98M | 84.31M |
Net Change In Cash | 35.32M | 18.01M | -9.60M | -10.10M | -59.66M | 97.91M | -25.40M | -5.10M | -31.40M | 44.32M |
Cash at end of period | 115.06M | 79.74M | 61.72M | 70.94M | 81.05M | 140.71M | 42.80M | 68.20M | 73.30M | 104.71M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |